TRANSFORMATIVE CELL-BASED THERAPIES
TO TREAT KIDNEY DISEASE PATIENTS
TO TREAT KIDNEY DISEASE PATIENTS
TRANSFORMATIVE CELL-BASED THERAPIES
TO TREAT KIDNEY DISEASE PATIENTS
TO TREAT KIDNEY DISEASE PATIENTS
ABOUT
LiveKidney is a clinical-stage cell therapy company, pioneering innovative therapies for kidney disease. The company is developing proprietary, pharmaceutical-grade hydrogel-based formulations of Umbilical Cord-derived Mesenchymal Stromal Cells (UC-MSCs) to treat advanced kidney disease and prevent its progression towards kidney failure. The company’s products allow the continuous release of bioactive compounds from the UC-MSCs to the kidneys via unique routes of administration, triggering anti-inflammatory and anti-fibrotic activity through a systemic and local effect. Our solutions could significantly alleviate the growing social burden and costs of kidney disease for patients and public healthcare organizations.
OUR PIPELINE:
LiveKidney is developing a novel cell therapy approach to address a significant clinical unmet need in kidney disease patients and related comorbidities. Our pipeline of products is based on our proprietary delivery platform of Umbilical Cord-derived Mesenchymal Stromal Cells and novel routes of administration.
Our lead product candidate, LK-SC001, is administered into the subcutaneous (SC) tissue and intended to treat autoimmune related kidney disease, including Lupus Nephritis, IgA Nephropathy, Rheumatoid Arthritis and Systemic Sclerosis. Our next-generation product candidate LK-PRAT002, is administered into the perirenal fat tissue and intended to improve kidney function for patients with Metabolic Syndrome.
In vitro studies > Animal studies > Clinical studies
* In collaboration with Medical University of South Carolina
CHRONIC KIDNEY DISEASE MARKET
Kidney Disease affects approximately one billion people globally, with annual spending in the US by Medicare alone amounting to 135 billion in 2023, including patients under 65 years old. Chronic kidney disease is a devastating progressive disease with no cure, often leading to renal failure, causing more than 4 million patients in the world to undergo dialysis with a 5-year survival rate of under 50%.
There is an increasing unmet medical need for safe and effective treatments that can improve kidney function in advanced kidney disease patients before they require Renal Replacement Therapy (dialysis or transplantation).
CHRONIC KIDNEY DISEASE MARKET
Kidney Disease affects approximately one billion people globally, with annual spending in the US by Medicare alone amounting to 135 billion in 2023, including patients under 65 years old. Chronic kidney disease is a devastating progressive disease with no cure, often leading to renal failure, causing more than 4 million patients in the world to undergo dialysis with a 5-year survival rate of under 50%.
There is an increasing unmet medical need for safe and effective treatments that can improve kidney function in advanced kidney disease patients before they require Renal Replacement Therapy (dialysis or transplantation).
AUTOIMMUNE RELATED KIDNEY DISEASE MARKET
Our lead product is targeting kidney disease caused by autoimmune diseases, initially focusing on Lupus Nephritis (LN), a particularly severe kidney disease manifested in 60% of Systemic Lupus Erythematosus (Lupus) patients and correlated with a higher mortality rate.
Lupus is a chronic autoimmune disease in which the immune system attacks healthy tissues, causing inflammation and damage to various parts of the body, including the kidneys, skin, joints and other organs. Symptoms can vary widely and may include fatigue, joint pain, rashes, and kidney problems. Lupus predominantly affects women of childbearing age, with 10-fold higher prevalence in females.
There are 5 million Lupus patients worldwide and the Lupus market is estimated at $2 billion. Potential future indications targeting additional multi-billion-dollar global autoimmune markets such as IgA nephropathy and kidney related Rheumatoid arthritis.
METABOLIC SYNDROME RELATED KIDNEY DISEASE MARKET
LiveKidney is also targeting kidney disease caused by metabolic syndrome, which is estimated to affect 1 of 3 adults in the US alone. Metabolic syndrome is a cluster of interrelated risk factors including diabetes, obesity, cardiovascular diseases, and fatty liver all of which contribute to kidney injury and to the progression of chronic kidney disease.
The Metabolic Syndrome Market is currently estimated at $85 Billion and is steadily growing with the increase in global prevalence and growing arsenal of therapeutics to manage these risk factors. Nevertheless, there is a significant unmet clinical need for safe and effective treatments that would halt the progression and deterioration of kidney disease towards kidney failure.
MANAGEMENT TEAM
Dr. Alon Yaar, DVM, MBA: CEO
Former CEO/COO of NeuroDerm (NASDAQ:NDRM) acquired by Mitsubishi Tanabe in 2017 in a $1.2 billion deal.
Dr. Masha Simanovsky, Ph.D.: Head of R&D
Expert in cell therapy and Extracellular Vesicles.
Dr. Shimon Amselem, Ph.D.: Head of CMC and Formulations
Expert in implantable biodegradable polymers. Significant contributions to five approvals by the FDA and four IND in Phase II/III clinical trials.
Avraham Hermon, MA: Head of IP
Israeli Patent Attorney and a US Patent Agent. Former Senior Manager at Teva Pharmaceutical Industries.
Roy Golan, CPA, LLM: Chief Financial Officer
Financial expert; Former CFO of NeuroDerm (NASDAQ:NDRM) that was acquired by Mitsubishi Tanabe and additional public companies.
Dorit Sokolov: Chief Business Officer
Longtime multi-disciplinary Biotech and HealthTech investor, Business Development expert and company builder.
Dr. Nadya Lisovoder, MD: Clinical Leader
Regulatory expert and a clinical adviser with vast experience in clinical studies in the pharma industry.
ADVISORY BOARD
Prof. Chaim Putterman
Professor of Medicine & Immunology at the Albert Einstein College of Medicine
Prof. Lilach O. Lerman
Professor of Medicine at The Renovascular Disease Research Laboratory, Mayo Clinic
Prof. Gary Gilkeson
Professor of Medicine, Associate Dean for Faculty Affairs and Faculty Development, Medical University of South Carolina
Eli Gelman
Chairman of the Board, Amdocs Limited, Chairman of the Executive Council of Tel Aviv University
TO LEARN MORE, OR PARTNER WITH LIVEKIDNEY,
CONTACT US TODAY!
